Posted by Michael Wonder on 05 Jul 2023
Sarepta Therapeutics announces sale of priority review voucher for $102 million
5 July 2023 - Sarepta Therapeutics today announced it had completed the sale of its rare paediatric disease priority review voucher.
Sarepta received a payment of $102 million upon completion of the sale.
